Here’s where the prevalence of Alzheimer’s dementia is highest and lowest
MBI deputy director Dr. Steven DeKosky commented for article in Neurology Today.
Posts tagged as
Steven DeKosky
Alzheimer’s disease is partly genetic − studying the genes that delay decline in some may lead to treatments for all
In The Conversation, UF neuroscientist Dr. Steven DeKosky explains new discoveries with treatment implications.
Medical community hopeful following FDA’s accelerated approval for Alzheimer’s disease treatment
Drs. Steven DeKosky and Glenn Smith discuss Lecanemab for WUFT article.
MBI deputy director surpasses 100K citations
Dr. Steven DeKosky has been cited over 100K times, per Google Scholar.
Predicting cognitive decline after dementia diagnosis
Dr. Steven DeKosky provides indicators to help “guestimate” rate of cognitive decline.
Dementia patients are at greater risk for COVID-19
Conversation article co-authored by Drs. Steven DeKosky and Michael Jaffee discusses new research about dementia and COVID-19 risk.
MBI directors discuss Alzheimer’s research and care
View a recording of Drs. Todd Golde and Steven DeKosky’s UF Health Webinar.
Blood tests for Alzheimer’s explained
In The Conversation, Drs. Golde and DeKosky explain the new test, which shows high accuracy in detecting chemicals specific to Alzheimer’s.
Dr. Jada Lewis named MBI co-deputy director
In her new role, Dr. Jada Lewis will continue to focus on the MBI's education and outreach activities.
Alzheimer’s disease: The right drug, the right time
In the journal Science, MBI leaders Drs. Steven DeKosky and Todd Golde discuss the challenges of developing effective Alzheimer's therapies and the road ahead.
